HK39094A - Aqueous steroid formulations for nasal administration - Google Patents
Aqueous steroid formulations for nasal administration Download PDFInfo
- Publication number
- HK39094A HK39094A HK39094A HK39094A HK39094A HK 39094 A HK39094 A HK 39094A HK 39094 A HK39094 A HK 39094A HK 39094 A HK39094 A HK 39094A HK 39094 A HK39094 A HK 39094A
- Authority
- HK
- Hong Kong
- Prior art keywords
- amount
- formulation
- inflammatory steroid
- polysorbate
- propylene glycol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Otolaryngology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (9)
- Verfahren zur Herstellung einer im wesentlichen nicht stechenden, wäßrigen entzündungshemmenden Steroidformulierung, die zur intranasalen Verabreichung geeignet ist, umfassend das Lösen von einem entzündungshemmenden Steroid in einer Menge zwischen 0,01% und 0,05% (Gew/Vol); Propylenglykol in einer Menge zwischen 2% und 10% (Gew/ Vol); PEG 400 in einer Menge zwischen 10% und 25% (Gew/Vol); und Polysorbat 20 in einer Menge zwischen 1% und 4% (Gew/Vol) in Wasser.
- Verfahren nach Anspruch 1, umfassend das Lösen von einem entzündungshemmendes Steroid in einer Menge zwischen 0,01% und 0,05% (Gew/Vol); Propylenglykol in einer Menge zwischen 2% und 10% (Gew/ Vol); PEG 400 in einer Menge zwischen 10% und 25% (Gew/Vol); Polysorbat 20 in einer Menge zwischen 1% und 4% (Gew/Vol); einer wirksamen Menge an Konservierungsmittel; einer wirksamen Menge an Antioxidans; einer wirksamen Menge an Stabilisator; und pH-Puffer, ausreichend, um den pH der resultierenden Lösung auf zwischen 3,5 und 7 einzustellen.
- Verfahren nach Anspruch 2, umfassend das Lösen von Konservierungsmittel in einer Menge zwischen 0,02% und 0,08% (Gew/Vol); Antioxidans in einer Menge zwischen 0,001% und 0,05% (Gew/Vol); und Stabilisator in einer Menge zwischen 0,005% und 0,05% (Gew/Vol).
- Verfahren nach den Ansprüchen 1, 2 oder 3, worin das entzündungshemmende Steroid Flunisolid ist.
- Verfahren nach den Ansprüchen 1, 2, 3 oder 4, welches außerdem das Lösen von Sorbit in einer Menge zwischen 0,00%1 und 5% (Gew/ Vol) umfaßt.
- Verfahren nach Anspruch 2, umfassend das Lösen von Flunisolid-Hemihydrat in einer Menge von 0,025% (Gew/Vol); Propylenglykol in einer Menge von 5% (Gew/Vol); PEG 400 in einer Menge von 20% (Gew/Vol); Polysorbat 20 in einer Menge von 2,50% (Gew/Vol); Benzalkoniumchlorid in einer Menge von 0,035% (Gew/Vol); Dinatrium-EDTA in einer Menge von 0,01% (Gew/Vol); BHT in einer Menge von 0,01% (Gew/Vol); Citronensäure in einer Menge von 0,005% (Gew/Vol); Natriumcitrat-Dihydrat in einer Menge von 0,00765% (Gew/ Vol); Sorbit in einer Menge von 2,00% (Gew/Vol); worin der pH der resultierenden Lösung auf 5,2 eingestellt wird.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/866,171 US4782047A (en) | 1986-05-22 | 1986-05-22 | Aqueous steroid formulations for nasal administration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK39094A true HK39094A (en) | 1994-04-29 |
Family
ID=25347059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK39094A HK39094A (en) | 1986-05-22 | 1994-04-21 | Aqueous steroid formulations for nasal administration |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US4782047A (de) |
| EP (1) | EP0246652B1 (de) |
| JP (1) | JP2521291B2 (de) |
| KR (1) | KR950008308B1 (de) |
| AT (1) | ATE65183T1 (de) |
| AU (1) | AU609718B2 (de) |
| CA (1) | CA1288048C (de) |
| DE (1) | DE3771389D1 (de) |
| DK (1) | DK175238B1 (de) |
| ES (1) | ES2031467T3 (de) |
| FI (1) | FI88459C (de) |
| GR (1) | GR3002317T3 (de) |
| HK (1) | HK39094A (de) |
| IE (1) | IE60259B1 (de) |
| IL (1) | IL82615A (de) |
| IT (1) | IT1205667B (de) |
| NO (1) | NO173365C (de) |
| NZ (1) | NZ220394A (de) |
| ZA (1) | ZA873663B (de) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4983595A (en) * | 1986-05-22 | 1991-01-08 | Syntex (U.S.A.) Inc. | Aqueous steroid formulations for nasal administration |
| JPH0311016A (ja) * | 1989-06-09 | 1991-01-18 | Tokyo Tanabe Co Ltd | ピリド［１，２―ａ］ピリミジン誘導体の水性製剤 |
| GB9103824D0 (en) * | 1991-02-23 | 1991-04-10 | Fisons Ag | Formulation |
| US5338732A (en) * | 1991-06-18 | 1994-08-16 | Bristol-Myers Squibb Company | Megestrol acetate formulation |
| WO1995011042A1 (en) * | 1993-10-21 | 1995-04-27 | Hisamitsu Pharmaceutical Co., Inc. | Pernasal composition and pernasal preparation containing the same |
| US5762917A (en) * | 1994-09-27 | 1998-06-09 | Virotex Corporation | Method and composition for cleansing wounds with minimal cytotoxicity for minimal scarring |
| US5976573A (en) * | 1996-07-03 | 1999-11-02 | Rorer Pharmaceutical Products Inc. | Aqueous-based pharmaceutical composition |
| US6241969B1 (en) * | 1998-06-26 | 2001-06-05 | Elan Corporation Plc | Aqueous compositions containing corticosteroids for nasal and pulmonary delivery |
| US8466134B1 (en) | 1998-06-26 | 2013-06-18 | Athena Neurosciences, Inc. | Aqueous compositions containing corticosteroids for nasal and pulmonary delivery |
| GB9918559D0 (en) * | 1999-08-07 | 1999-10-06 | Glaxo Wellcome Kk | Novel pharmaceutical formulation |
| US20040115133A1 (en) * | 2000-05-10 | 2004-06-17 | Wermeling Daniel P. | Intranasal opioid compositions |
| US6610271B2 (en) * | 2000-05-10 | 2003-08-26 | University Of Kentucky Research Foundation | System and method for intranasal administration of lorazepam |
| US20060083691A1 (en) * | 2000-05-10 | 2006-04-20 | Wermeling Daniel P | Intranasal opioid compositions, delivery devices and methods of using same |
| AU2001286518A1 (en) | 2000-08-15 | 2002-02-25 | University Of Kentucky Research Foundation | Programmable multi-dose intranasal drug delivery device |
| US20040176359A1 (en) * | 2001-02-20 | 2004-09-09 | University Of Kentucky Research Foundation | Intranasal Benzodiazepine compositions |
| GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
| CA2493764C (en) | 2002-08-01 | 2011-05-24 | Aesgen, Inc. | Improved treatment of cancer with glutamine |
| US7148211B2 (en) * | 2002-09-18 | 2006-12-12 | Genzyme Corporation | Formulation for lipophilic agents |
| US7404489B1 (en) | 2003-03-04 | 2008-07-29 | Qol Medical, Llc | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
| JP5238779B2 (ja) * | 2003-04-25 | 2013-07-17 | ロート製薬株式会社 | 点鼻剤 |
| JP4632687B2 (ja) * | 2003-04-25 | 2011-02-16 | ロート製薬株式会社 | 点鼻剤 |
| WO2005065185A2 (en) * | 2003-12-24 | 2005-07-21 | Collegium Pharmaceuticals, Inc. | Temperature-stable formulations, and methods of development thereof |
| GB0400804D0 (en) | 2004-01-14 | 2004-02-18 | Innoscience Technology Bv | Pharmaceutical compositions |
| US20060045850A1 (en) * | 2004-08-30 | 2006-03-02 | Qpharma, Llc | Nasal delivery of cyclodextrin complexes of anti-inflammatory steroids |
| JP5607291B2 (ja) | 2004-11-24 | 2014-10-15 | メダ ファーマシューティカルズ インコーポレイテッド | アゼラスチンを含む組成物およびその使用方法 |
| WO2007022345A2 (en) * | 2005-08-17 | 2007-02-22 | Fleming And Company, Pharmaceuticals | Vitamin b12 nasal spray and method of use |
| KR100767976B1 (ko) | 2006-08-25 | 2007-10-18 | 한국유나이티드제약 주식회사 | 비내 건조증에 효과적인 약제학적 조성물 |
| CN101678112B (zh) | 2007-01-19 | 2016-08-31 | 哈南亚有限公司 | 用于递送治疗剂的方法和组合物 |
| US20080275030A1 (en) | 2007-01-19 | 2008-11-06 | Sveinbjorn Gizurarson | Methods and Compositions for the Delivery of a Therapeutic Agent |
| JP2011001317A (ja) * | 2009-06-19 | 2011-01-06 | Fumakilla Ltd | 鼻用洗浄剤 |
| WO2014145067A1 (en) * | 2013-03-15 | 2014-09-18 | Medicis Pharmaceutical Corporation | Topical compositions of flunisolide and methods of treatment |
| US11135155B2 (en) | 2014-07-08 | 2021-10-05 | Hikma Pharmaceuticals Usa Inc. | Liquid naloxone spray |
| JP6097787B2 (ja) * | 2015-06-09 | 2017-03-15 | パル ファーマシューティカル， インコーポレーテッド | 鼻内送達用シアノコバラミン低粘度水性製剤 |
| US11510859B2 (en) | 2015-07-16 | 2022-11-29 | Marinomed Biotech Ag | Method for improving aqueous solubility of water-insoluble or slightly water-soluble drugs |
| EA036233B1 (ru) | 2015-07-16 | 2020-10-16 | Мариномед Биотек Аг | Способ улучшения растворимости в воде лекарственных средств, нерастворимых или слаборастворимых в воде |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2989437A (en) * | 1955-06-08 | 1961-06-20 | Upjohn Co | Anti-inflammatory and anti-bacterial decongestant nasal spray compositions |
| MX3864E (es) * | 1975-05-27 | 1981-08-26 | Syntex Corp | Un proceso para prepara el compuesto cristalino 6-fluiro-11b 21-dihiroxi-16 17-isopropilidendioxipregna-1 4-dien-3 20-diona |
| DE2750090A1 (de) * | 1976-11-19 | 1978-06-01 | Sandoz Ag | Neue verabreichungsformen fuer organische verbindungen |
| US4444762A (en) * | 1980-04-04 | 1984-04-24 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacyclopentan-2-ones |
| US4344940A (en) * | 1981-11-30 | 1982-08-17 | E. R. Squibb & Sons, Inc. | Steroid formulation containing dipotassium EDTA |
| US4603131A (en) * | 1982-04-26 | 1986-07-29 | Bernstein Joel E | Method and composition for treating and preventing irritation of the mucous membranes of the nose |
-
1986
- 1986-05-22 US US06/866,171 patent/US4782047A/en not_active Expired - Lifetime
-
1987
- 1987-05-21 AU AU73273/87A patent/AU609718B2/en not_active Ceased
- 1987-05-21 CA CA000537690A patent/CA1288048C/en not_active Expired - Lifetime
- 1987-05-21 JP JP62126846A patent/JP2521291B2/ja not_active Expired - Lifetime
- 1987-05-21 EP EP87107416A patent/EP0246652B1/de not_active Expired - Lifetime
- 1987-05-21 ZA ZA873663A patent/ZA873663B/xx unknown
- 1987-05-21 DE DE8787107416T patent/DE3771389D1/de not_active Expired - Lifetime
- 1987-05-21 AT AT87107416T patent/ATE65183T1/de not_active IP Right Cessation
- 1987-05-21 FI FI872231A patent/FI88459C/fi not_active IP Right Cessation
- 1987-05-21 NO NO872127A patent/NO173365C/no unknown
- 1987-05-21 ES ES198787107416T patent/ES2031467T3/es not_active Expired - Lifetime
- 1987-05-21 NZ NZ220394A patent/NZ220394A/en unknown
- 1987-05-21 IE IE133587A patent/IE60259B1/en not_active IP Right Cessation
- 1987-05-21 IL IL82615A patent/IL82615A/xx not_active IP Right Cessation
- 1987-05-21 KR KR1019870005032A patent/KR950008308B1/ko not_active Expired - Fee Related
- 1987-05-21 DK DK198702586A patent/DK175238B1/da active
- 1987-05-21 IT IT20621/87A patent/IT1205667B/it active
-
1991
- 1991-07-18 GR GR91400394T patent/GR3002317T3/el unknown
-
1994
- 1994-04-21 HK HK39094A patent/HK39094A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| GR3002317T3 (en) | 1992-12-30 |
| NO872127D0 (no) | 1987-05-21 |
| EP0246652A3 (en) | 1988-02-03 |
| AU7327387A (en) | 1987-11-26 |
| FI872231L (fi) | 1987-11-23 |
| EP0246652B1 (de) | 1991-07-17 |
| AU609718B2 (en) | 1991-05-09 |
| KR950008308B1 (ko) | 1995-07-27 |
| CA1288048C (en) | 1991-08-27 |
| IL82615A (en) | 1991-11-21 |
| NO872127L (no) | 1987-11-23 |
| EP0246652A2 (de) | 1987-11-25 |
| NO173365B (no) | 1993-08-30 |
| NZ220394A (en) | 1990-04-26 |
| KR870010862A (ko) | 1987-12-18 |
| IT8720621A0 (it) | 1987-05-21 |
| ES2031467T3 (es) | 1992-12-16 |
| DK258687D0 (da) | 1987-05-21 |
| FI872231A0 (fi) | 1987-05-21 |
| IE871335L (en) | 1987-11-22 |
| NO173365C (no) | 1993-12-08 |
| DK258687A (da) | 1987-11-23 |
| FI88459C (fi) | 1993-05-25 |
| IT1205667B (it) | 1989-03-31 |
| IE60259B1 (en) | 1994-06-29 |
| US4782047A (en) | 1988-11-01 |
| DE3771389D1 (de) | 1991-08-22 |
| DK175238B1 (da) | 2004-07-19 |
| ZA873663B (en) | 1988-12-28 |
| JP2521291B2 (ja) | 1996-08-07 |
| ATE65183T1 (de) | 1991-08-15 |
| JPS62283927A (ja) | 1987-12-09 |
| IL82615A0 (en) | 1987-11-30 |
| FI88459B (fi) | 1993-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0246652B1 (de) | Wässerige Steroidformulierungen zur nasalen Verabreichung | |
| US4983595A (en) | Aqueous steroid formulations for nasal administration | |
| AU642210B2 (en) | Therapeutic use of indole-3-yl-carboxylic acid endo-8- methyl-8-aza-bicyclo(3,2,1)oct-3-yl ester | |
| JP2515788B2 (ja) | 目の炎症の治療薬 | |
| US6514520B2 (en) | Stabilized antihistamine syrup | |
| CA2822683C (en) | Bepotastine compositions | |
| US4711906A (en) | Liquid diclofenac preparations | |
| IL142494A (en) | Storable active substance concentrate with formoterol | |
| EP0973501B1 (de) | Wässrige suspension zur nasalen verabreichung von loteprednol | |
| HU192246B (en) | Process for producing of galenic compositions consisting of calcitonin | |
| WO2012127497A1 (en) | Stable pharmaceutical compositions of ketorolac or salts thereof | |
| US5538989A (en) | Fenbendazole formulations | |
| EP1782816B1 (de) | Medizinische zusammensetzung auf wasserbasis mit azithromycin und herstellungsverfahren dafür | |
| JP4393192B2 (ja) | リバビリンシロップ処方物 | |
| EP4048230B1 (de) | Orale gliptinzusammensetzungen und verfahren zur herstellung davon | |
| EP1543826B1 (de) | Konzentrierte wässrige Ambroxollösung | |
| GB2162745A (en) | Nasal compositions | |
| EP2289489B1 (de) | Zusammensetzungen mit Cyclohexylaminen und Aminoadamantanen | |
| EP3189855A1 (de) | Orale pharmazeutische lösungen mit hydrocortison-natrium-phosphat | |
| JPH02503439A (ja) | 局所的眼科用途の為のトブラマイシンとステロイドの組合わせ | |
| GB2100599A (en) | Pharmaceutical preparation for treating glaucoma and ocular hypertension | |
| JPH0354647B2 (de) | ||
| EP1121935B1 (de) | Arzneimittel, welches ein Peptid kleiner oder mittlerer Grösse enthält |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PF | Patent in force | ||
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20060521 |